Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
COMMAND GT2/3: Daclatasvir + Peg-IFN/RBV in HCV Genotype 2/3
NCT01257204Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of daclatasvir in hepatitis C (HCV), sponsored by Bristol Myers Squibb. Started Dec 2010; status: completed.
02
Drugs
daclatasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01257204.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01257204.